Background: JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase activation, has been incorporated into the WHO classification and diagnostic criteria of myeloid neoplasms. Although various approaches such as restriction fragment length polymorphism, amplification refractory mutation system and real-time PCR have been developed for its detection, a generic rapid closed-tube method, which can be utilized on routine genetic testing instruments with stability and cost-efficiency, has not been described. Methodology/Principal Findings: Asymmetric PCR for detection of JAK2 V617F with a 39-blocked unlabeled probe, saturate dye and subsequent melting curve analysis was performed on a Rotor-GeneH Q real-ti...
Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic m...
Abstract The most important criterion in the diagnosis of myeloproliferative diseases is the JAK2 (...
The JAK2V617F mutation has emerged as an essential molecular determinant of myeloproliferative neopl...
JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase acti...
BACKGROUND: JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and...
<div><p>Detection of the <i>JAK2</i>V617F mutation is essential for diagnosing patients with classic...
Introduction: Myeloproliferative neoplasm (MPN) is a group of myeloid disorders which leads to eryt...
BACKGROUND: Myeloproliferative disorders are characterized by clonal expansion of normal mature bloo...
During the last 5 years, it was discovered that the JAK2V617F somatic mutation is present in virtual...
Detection of the JAK2V617F mutation is essential for diagnosing patients with classical myeloprolife...
The activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617F) is associated w...
An acquired mutation in Janus kinase 2 (JAK2), V617F, has recently been identified in human myelopro...
Background/PurposeThe activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617...
Dissertation (MSc)--University of Pretoria, 2016.In 2005, a mutation located at exon 14 of the Janus...
Diverse JAK2 exon 12 mutations have been described in patients with V617F-negative polycythemia vera...
Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic m...
Abstract The most important criterion in the diagnosis of myeloproliferative diseases is the JAK2 (...
The JAK2V617F mutation has emerged as an essential molecular determinant of myeloproliferative neopl...
JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase acti...
BACKGROUND: JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and...
<div><p>Detection of the <i>JAK2</i>V617F mutation is essential for diagnosing patients with classic...
Introduction: Myeloproliferative neoplasm (MPN) is a group of myeloid disorders which leads to eryt...
BACKGROUND: Myeloproliferative disorders are characterized by clonal expansion of normal mature bloo...
During the last 5 years, it was discovered that the JAK2V617F somatic mutation is present in virtual...
Detection of the JAK2V617F mutation is essential for diagnosing patients with classical myeloprolife...
The activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617F) is associated w...
An acquired mutation in Janus kinase 2 (JAK2), V617F, has recently been identified in human myelopro...
Background/PurposeThe activating JAK2 mutation with a G-C to T-A transversion at codon 617 (JAK2V617...
Dissertation (MSc)--University of Pretoria, 2016.In 2005, a mutation located at exon 14 of the Janus...
Diverse JAK2 exon 12 mutations have been described in patients with V617F-negative polycythemia vera...
Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic m...
Abstract The most important criterion in the diagnosis of myeloproliferative diseases is the JAK2 (...
The JAK2V617F mutation has emerged as an essential molecular determinant of myeloproliferative neopl...